✦ LIBER ✦

Phase I safety and immunogenicity trial of FMP1/AS02A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine

✍ Scribed by Christian F. Ockenhouse; Evelina Angov; Kent E. Kester; Carter Diggs; Lorraine Soisson; James F. Cummings; Ann V. Stewart; Dupeh R. Palmer; Babita Mahajan; Urszula Krzych; Nadia Tornieporth; M. Delchambre; M. Vanhandenhove; Opokua Ofori-Anyinam; Joe Cohen; Jeffrey A. Lyon; D. Gray Heppner

Book ID: 116958581
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 203 KB
Volume: 24
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2005.11.028

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 1 randomized double-blind safety a

Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya

✍ José A. Stoute; Joash Gombe; Mark R. Withers; Joram Siangla; Denise McKinney; Me 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 325 KB

Safety and immunogenicity of a three-com

Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children

✍ Blaise Genton; Fadwa Al-Yaman; Inoni Betuela; Robin F Anders; Allan Saul; Kay Ba 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 129 KB

Phase 1 safety and immunogenicity trial

Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults

✍ Mark A. Pierce; Ruth D. Ellis; Laura B. Martin; Elissa Malkin; Eveline Tierney; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 330 KB

Phase I dose escalation safety and immun

Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research

✍ Mark E. Polhemus; Alan J. Magill; James F. Cummings; Kent E. Kester; Chris F. Oc 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 646 KB

Safety and immunogenicity of an inactiva

Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial

✍ Jiangtao Lin; Jiansan Zhang; Xiaoping Dong; Hanhua Fang; Jiangting Chen; Nan Su; 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 135 KB

Evaluation of the safety and immunogenic

Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys

✍ S. Pichyangkul; P. Tongtawe; U. Kum-Arb; K. Yongvanitchit; M. Gettayacamin; M.R. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 337 KB